← All trials
NCT03201159
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2017
- Primary completion
- Feb 27, 2018
- Completion date
- Feb 27, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MassachusettsLead sponsor
- University of MassachusettsOverall official - principal investigator
- University of MassachusettsSponsor investigator
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)Collaborator
- University of LouisvilleCollaborator
- The University of Texas, DallasCollaborator
- The Cleveland ClinicCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.